Ceftaroline Fosamil: A Brief Clinical Review

被引：27
作者：
Shirley D.-A.T. [1 ]
Heil E.L. [2 ]
Johnson J.K. [3 ,4 ]
机构：
[1] Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore
[2] Department of Pharmacy, University of Maryland Medical Center, Baltimore
[3] Departments of Pathology and Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, 21201
[4] Microbiology and Virology Laboratories, University of Maryland Medical Center, Baltimore, MD, 21201
来源：
Infectious Diseases and Therapy | 2013年 / 2卷 / 2期
关键词：
Avibactam; Bacterial infection; Ceftaroline; Cephalosporin; Community-acquired infection; Methicillin-resistant S. aureus; Pneumonia; S; aureus; pneumoniae; Skin infection;
D O I：
10.1007/s40121-013-0010-x
中图分类号：
学科分类号：
摘要：
Ceftaroline is a novel cephalosporin with a favorable tolerability profile and broad in vitro activity against many resistant Gram-positive and common Gram-negative organisms. Ceftaroline fosamil is the first cephalosporin to be approved by the United States Food and Drug Administration (FDA) for the treatment of adults with acute bacterial skin and soft tissue infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). It is also approved by the FDA for the treatment of adults with community-acquired bacterial pneumonia, including cases caused by Streptococcus pneumoniae (with or without concurrent bacteremia), although there are no data at this time to support the use of ceftaroline fosamil for the treatment of pneumonia caused by MRSA. Ceftaroline fosamil is likewise approved by the European Commission for the treatment of adults with complicated skin and soft tissue infections or community-acquired pneumonia. This review summarizes the pharmacokinetic and microbiologic properties of ceftaroline, as well as the safety and efficacy data that led to its approval by the FDA in 2010 and the European Commission in 2012. Future directions to be addressed are also highlighted. © 2013 The Author(s).
引用
收藏
页码：95 / 110
页数：15
相关论文
共 92 条
[21]  
Sader H.S., Fritsche T.R., Jones R.N., Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 52, pp. 1153-1155, (2008)
[22]  
Vidaillac C., Leonard S.N., Rybak M.J., In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model, Antimicrob Agents Chemother, 53, pp. 4712-4717, (2009)
[23]  
Saravolatz L., Pawlak J., Johnson L., In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates, Antimicrob Agents Chemother, 54, pp. 3027-3030, (2010)
[24]  
Jacqueline C., Amador G., Batard E., Et al., Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus, J Antimicrob Chemother, 66, pp. 863-866, (2011)
[25]  
Zhanel G.G., Rossnagel E., Nichol K., Et al., Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model, J Antimicrob Chemother, 66, pp. 1301-1305, (2011)
[26]  
Steed M., Vidaillac C., Rybak M.J., Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model, Antimicrob Agents Chemother, 55, pp. 3522-3526, (2011)
[27]  
Mushtaq S., Warner M., Ge Y., Kaniga K., Livermore D.M., In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes, J Antimicrob Chemother, 60, pp. 300-311, (2007)
[28]  
Clark C., McGhee P., Appelbaum P.C., Kosowska-Shick K., Multistep resistance development studies of ceftaroline in Gram-positive and -negative bacteria, Antimicrob Agents Chemother, 55, pp. 2344-2351, (2011)
[29]  
Mushtaq S., Warner M., Williams G., Critchley I., Livermore D.M., Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae, J Antimicrob Chemother, 65, pp. 1428-1432, (2010)
[30]  
Citron D.M., Tyrrell K.L., Merriam C.V., Goldstein E.J., In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria, Antimicrob Agents Chemother, 54, pp. 1627-1632, (2010)
12345678910